acut
respiratori
failur
contribut
significantli
nonrelaps
mortal
allogen
hematopoiet
stem
cell
transplant
although
trend
improv
surviv
time
mortal
remain
unaccept
high
understand
pathophysiolog
earli
respiratori
failur
opportun
target
therapi
assess
patient
risk
optim
use
noninvas
posit
pressur
ventil
strategi
improv
alveolar
recruit
appropri
fluid
manag
care
patient
chronic
lung
diseas
importantli
team
approach
critic
care
transplant
servic
may
improv
outcom
allogen
hematopoiet
stem
cell
transplant
hsct
cur
modal
patient
certain
hematolog
malign
nonmalign
disord
posttransplant
pulmonari
complic
acut
respiratori
failur
arf
contribut
significantli
morbid
mortal
procedur
although
incid
arf
hsct
decreas
time
mortal
remain
high
particularli
patient
requir
endotrach
intub
mechan
ventil
henc
team
approach
transplant
intens
care
ancillari
servic
essenti
improv
outcom
review
highlight
approach
arf
perspect
focu
identifi
patient
risk
arf
transplant
updat
definit
pulmonari
complic
discuss
newer
insight
pathophysiolog
novel
therapeut
option
explor
role
brochoalveolar
lavag
bal
context
newli
develop
infecti
diagnost
array
includ
posteintens
care
icu
rehabilit
lung
injuri
occur
hsct
recipi
account
approxim
transplantationrel
mortal
lung
injuri
may
classifi
noninfecti
infecti
noninfecti
lung
injuri
may
acut
idiopath
pneumonia
syndrom
ip
chronic
lead
either
obstruct
lung
diseas
old
restrict
lung
diseas
rld
old
defin
basi
global
lung
initi
gli
equat
endors
american
thorac
societi
european
respiratori
societi
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
less
lower
limit
normal
rld
defin
total
lung
capac
less
predict
nation
institut
health
nih
workshop
propos
broad
definit
ip
includ
widespread
alveolar
injuri
absenc
activ
lower
respiratori
infect
cardiogen
caus
acut
renal
failur
iatrogen
fluid
overload
hsct
diagnost
criteria
ip
updat
base
offici
american
thorac
societi
research
statement
tabl
classifi
entiti
base
anatom
site
inflamm
relat
either
interstiti
vascular
airway
tissu
unclassifi
tabl
clinic
symptom
includ
cough
dyspnea
hypoxemia
without
fever
chest
radiographi
may
show
bilater
infiltr
incid
ip
first
day
allogen
hsct
myeloabl
condit
risk
factor
includ
total
bodi
irradi
older
recipi
age
acut
graftversushost
diseas
gvhd
incid
ip
lower
nonmyeloabl
condit
howev
clinic
cours
result
arf
death
diagnosi
establish
unchang
ipsrel
mortal
histor
high
despit
treatment
corticosteroid
noninfecti
lung
injuri
occasion
occur
autolog
hsct
murin
model
ip
support
lung
target
cellemedi
injuri
hsct
increas
tnfa
found
bal
fluid
mice
ip
causal
role
tnfa
establish
neutral
cytokin
experiment
hsct
model
tnfaeindepend
pathway
may
also
contribut
pathophysiolog
ip
lipopolysaccharid
level
increas
bal
fluid
mice
ip
transloc
lipopolysaccharid
across
gut
mucosa
damag
earli
posttransplant
period
stimul
releas
cytokin
contribut
lung
damag
develop
acut
gvhd
lung
also
sensit
reactiv
oxygen
speci
whose
product
enhanc
set
chang
exhal
nitric
oxid
marker
airway
inflamm
use
guid
risk
stratif
noninfecti
lung
injuri
lung
transplant
surfact
dysfunct
caus
decreas
synthesi
alveolar
type
ii
cell
degrad
oxid
like
contribut
ip
transtrach
instil
human
surfact
proteina
attenu
manifest
ip
mice
keratinocyt
growth
factor
growth
factor
type
ii
pneumocyt
vivo
keratinocyt
growth
factor
increas
lung
surfact
level
may
detoxifi
reactiv
oxygen
speci
lower
serum
tnfa
level
diminish
lung
injuri
ip
mous
model
investig
also
found
increas
express
ccchemokin
ligand
murin
lung
model
ip
parallel
recruit
leukocyt
cellular
express
chemokin
receptor
gener
lung
parenchyma
promot
ip
via
induct
differenti
high
plasma
concentr
time
diagnosi
associ
lack
respons
tnf
inhibit
blockad
signal
monoclon
antibodi
tocilizumab
genetech
inc
san
francisco
ca
reduc
gvhd
preserv
graftversustumor
effect
mice
summari
inflammatori
factor
contribut
ip
strong
foundat
basic
scienc
offer
promis
target
therapi
ip
syndrom
wide
clinic
spectrum
depend
site
diseas
tabl
engraft
syndrom
defin
consensu
accord
criteria
outlin
spitzer
mainli
character
fever
rash
noncardiogen
pulmonari
edema
occur
time
neutrophil
recoveri
hsct
risk
report
higher
among
male
recipi
myeloabl
condit
total
bodi
irradi
tbi
cgi
unrel
donor
hsct
patient
engraft
syndrom
higher
risk
develop
gvhd
biomark
suppress
tumorigen
interleukin
receptor
alpha
tumor
necrosi
factor
receptor
elev
describ
patient
gvhd
diffus
alveolar
hemorrhag
dah
origin
pulmonari
microvasculatur
respons
alveolar
injuri
may
noninfecti
secondari
chemotherapi
radiat
immunemedi
event
due
system
pulmonari
infect
older
age
allogen
donor
sourc
myeloabl
condit
acut
sever
gvhd
independ
predict
increas
risk
dah
probabl
surviv
poor
mortal
noninfecti
infectionassoci
dah
noninfecti
pulmonari
complic
includ
classif
ip
includ
radiat
pneumon
pulmonari
alveolar
proteinosi
involv
lung
parenchyma
pulmonari
venoocclus
diseas
pulmonari
cytolyt
thrombi
transfusionrel
acut
lung
injuri
pulmonari
arteri
hypertens
pulmonari
thromboembol
involv
vascular
endothelium
tabl
bronchiol
obliteran
syndrom
bo
progress
insidi
lung
diseas
manifest
new
fix
airflow
obstruct
due
progress
circumferenti
fibrosi
cicatr
small
termin
airway
pathogenesi
bo
involv
alloimmun
nonalloimmun
infecti
chemoradiotherapi
injuri
process
associ
chronic
gvhd
bo
well
accept
cryptogen
organ
pneumonia
cop
formerli
known
bronchiol
obliteran
organ
pneumonia
inflammatori
diseas
hla
dispar
femaletomal
hsct
peripher
blood
stem
cell
transplant
tbibas
regimen
associ
increas
risk
cop
associ
acut
chronic
gvhd
subsequ
develop
cop
note
although
cop
bo
associ
chronic
gvhd
occur
similar
time
frame
patient
bo
present
without
fever
wheez
wherea
patient
cop
present
fever
crackl
physic
examin
notabl
differ
describ
tabl
lung
biopsi
recommend
diagnosi
cop
bo
caus
obstruct
lung
diseas
copbronchiol
obliteran
organ
pneumonia
caus
rld
may
use
interchang
clinic
radiolog
pulmonari
function
histolog
differ
describ
tabl
although
syndrom
ip
exclud
infect
infecti
lung
injuri
role
pathophysiolog
dah
exacerb
bo
bal
strongli
consid
patient
diffus
lung
infiltr
transplant
avail
autom
multiplex
pcr
rapid
accur
detect
respiratori
pathogen
increas
assay
sensit
specif
respect
biofirefilmarray
respiratori
panel
biofir
diagnost
inc
salt
lake
citi
ut
usa
target
pathogen
includ
virus
subtyp
bacteria
perform
minim
sampl
manipul
although
bal
specimen
hsct
patient
day
posit
infect
retrospect
studi
perform
improv
diagnost
array
yield
may
higher
procedur
complic
note
case
patient
requir
intub
mechan
ventil
within
hour
procedur
bal
data
result
chang
medic
manag
approxim
case
diagnost
yield
bal
high
perform
within
hour
clinic
present
procedur
complic
occur
patient
studi
pathogen
detect
lower
respiratori
tract
bal
often
differ
detect
upper
respiratori
tract
nasopharyng
wash
addit
assay
galactomannan
bal
neg
predict
valu
diagnos
proven
probabl
invas
fungal
infect
ifi
institut
corticosteroid
therapi
ip
may
caus
harm
benefit
context
undiagnos
infect
risk
associ
empir
antimicrobi
therapi
includ
medic
side
effect
develop
resist
compound
potenti
harm
delay
target
manag
isol
lung
involv
alon
account
death
due
proven
ifi
hsct
review
case
aspergillosi
period
institut
case
isol
abdomin
pelvic
diseas
note
lung
common
organ
involv
concurr
abdomin
diseas
ifi
lung
decreas
better
antifung
prophylaxi
preemptiv
screen
galactomannan
use
pcr
molecular
approach
matrixassist
laser
desorpt
ioniz
prove
promis
clinic
trial
use
standard
may
reduc
need
antifung
therapi
prophylaxi
preemptiv
therapi
base
surveil
molecular
screen
substanti
reduc
incid
cytomegaloviru
diseas
transplant
novel
drug
maribavir
letermovir
brincidofovir
undergo
clinic
trial
adopt
cellular
therapi
promis
restor
antivir
immun
absenc
signific
toxic
low
risk
induct
gvhd
novel
sialidas
fusion
protein
parainfluenza
viru
undergo
random
placebocontrol
clinic
trial
older
children
adult
treatment
oral
respiratori
syncyti
viruseentri
inhibitor
reduc
viral
load
sever
diseas
doubleblind
placebocontrol
studi
healthi
adult
approach
translat
clinic
practic
may
reduc
infectiousassoci
lung
injuri
transplant
patient
risk
pulmonari
dysfunct
transplant
identifi
pretransplant
histolog
reveal
thrombi
small
medium
distal
pulmonari
vessel
associ
pulmonari
infarct
transfusionrel
acut
lung
injuri
present
fever
chill
leukopenia
acut
dyspnea
hypotens
within
hour
cellular
product
infus
histolog
reveal
aggreg
leukocyt
pulmonari
vasculatur
pulmonari
arteri
hypertens
insidi
onset
dyspnea
within
month
transplant
detect
followup
echocardiogram
histolog
reveal
intim
hyperplasia
small
pulmonari
vessel
pulmonari
thromboembol
acut
onset
fever
dri
cough
dyspnea
due
embolu
pulmonari
vein
detect
chest
ct
lung
angiographi
evalu
base
pulmonari
function
test
pft
children
noninfecti
infecti
pulmonari
complic
transplant
significantli
lower
forc
expiratori
flow
vital
capac
pretransplant
pft
lower
fev
fvc
rld
predict
wors
overal
surviv
reduc
pretransplant
fev
fvc
associ
higher
risk
earli
respiratori
failur
wors
lung
function
score
combin
measur
fev
singlebreath
diffus
capac
carbon
monoxid
associ
poor
surviv
patient
may
benefit
non
tbibas
condit
lung
shield
prevent
gvhd
close
monitor
pft
transplant
patient
receiv
myeloabl
condit
much
greater
declin
fev
compar
receiv
nonmyeloabl
condit
higher
mortal
risk
especi
pretransplant
fev
less
patient
combin
ventilationdiffus
capac
deficit
transplant
reduct
lung
tbi
dose
improv
surviv
patient
abnorm
pretransplant
lung
function
other
evolv
pulmonari
dysfunct
transplant
approach
conduct
weekli
multidisciplinari
round
conjunct
intens
care
team
discuss
strategi
prevent
respiratori
compromis
neutral
tnfa
reduc
lung
injuri
experiment
allogen
hsct
etanercept
enbrel
immunex
seattl
wa
dimer
protein
consist
solubl
tnf
receptor
fuse
fc
portion
type
molecul
signific
improv
day
surviv
report
sever
singleinstitut
nonrandom
studi
combin
etanercept
corticosteroid
random
multicent
doubleblind
placebocontrol
trial
etanercept
treatment
ip
allogen
hsct
adult
halt
accrual
subject
preclud
definit
conclus
etanercept
administr
associ
increas
toxic
increas
incid
opportunist
infect
risk
relaps
compar
placebo
control
multicent
phase
ii
trial
etanercept
corticosteroid
children
ip
accru
evalu
patient
complet
respons
seen
patient
median
time
respons
day
respons
rate
higher
patient
requir
mechan
ventil
studi
entri
overal
surviv
year
therapi
compar
favor
histor
data
earli
recognit
disord
bal
exclud
infecti
pathogen
therapi
etanercept
corticosteroid
may
improv
outcom
ip
corticosteroid
often
dramat
effect
patient
engraft
syndrom
dose
mkgday
day
taper
suggest
higher
nonrelaps
mortal
lower
overal
surviv
year
patient
engraft
syndrom
report
despit
use
corticosteroid
highdos
corticosteroid
alter
poor
outcom
associ
dah
larg
retrospect
studi
patient
dah
receiv
steroid
mgday
lower
mortal
compar
receiv
mediumand
highdos
steroid
adjunct
treatment
aminocapro
acid
produc
differ
outcom
mortal
high
previou
studi
small
group
patient
show
use
aminocapro
acid
corticosteroid
safe
favor
effect
surviv
factor
viia
also
use
addit
steroid
control
acut
stage
dah
howev
recent
retrospect
studi
use
factor
viia
combin
steroid
improv
time
resolut
dah
durat
mechan
ventil
hospit
mortal
compar
outcom
steroid
alon
avoid
system
steroid
treatment
inhal
budesonideformoterol
shown
significantli
improv
fev
earli
month
treatment
initi
random
doubleblind
placebocontrol
studi
patient
moder
sever
bo
trial
use
fluticason
azithromycin
montelukast
bo
ongo
case
seri
patient
show
similar
chang
fev
compar
histor
group
receiv
highdos
corticosteroid
reduc
system
corticosteroid
exposur
reduc
treatmentrel
morbid
bo
chang
efficaci
etanercept
addit
efficaci
ip
may
potenti
role
treatment
subacut
lung
injuri
patient
least
day
allogen
hsct
etanercept
well
toler
popul
object
respons
seen
patient
random
doubleblind
placebocontrol
trial
inhal
cyclosporin
addit
system
immunosuppress
lung
transplant
improv
surviv
extend
period
chronic
rejectionfre
surviv
histolog
chronic
reject
lung
transplant
present
bo
excel
neg
predict
valu
persist
low
fraction
exhal
nitric
oxid
earli
diagnosi
bo
lung
transplant
suggest
valu
explor
novel
diagnost
therapeut
modal
treat
bo
hsct
placebocontrol
trial
azithromycin
therapi
given
altern
day
week
patient
bo
lung
transplant
show
signific
improv
fev
earli
identif
manag
patient
evolv
pulmonari
dysfunct
develop
symptom
critic
improv
outcom
nih
symptombas
lung
score
score
symptom
score
short
breath
climb
stair
score
short
breath
flat
ground
score
short
breath
rest
requir
oxygen
associ
nonrelaps
mortal
overal
surviv
even
nih
symptombas
lung
score
associ
wors
overal
surviv
compar
score
worsen
nih
symptombas
lung
score
associ
increas
mortal
frequent
monitor
pft
use
indic
may
detect
chang
symptom
develop
guid
manag
equat
base
larg
refer
popul
age
year
produc
agespecif
spirometr
indic
lower
limit
normal
use
fix
threshold
fev
fvc
could
misdiagnos
patient
refer
pft
comput
tomographyebas
imag
biomark
may
provid
uniqu
signatur
diagnosi
small
airway
diseas
diseas
progress
clinic
biomark
may
aid
earli
diagnosi
prognost
patient
evolv
pulmonari
dysfunct
serum
level
suppress
tumorigen
significantli
elev
patient
acut
exacerb
idiopath
pulmonari
fibrosi
level
invers
correl
pao
fio
symptom
typic
respond
corticosteroid
prevent
azithromycin
treatment
reduc
noninfecti
lung
injuri
acut
gvhd
murin
model
allogen
hsct
macrolid
patient
acut
lung
injuri
shown
improv
surviv
shorten
time
success
discontinu
mechan
ventil
cellbas
therapi
bone
marrowederiv
mesenchym
stem
cell
potenti
attract
new
therapeut
option
treat
patient
acut
respiratori
distress
syndrom
ard
shown
efficaci
repair
establish
injuri
anim
play
role
pathophysiolog
ip
blockad
toclilizumab
reduc
gvhd
mous
model
addit
tocilizumab
standard
gvhd
prophylaxi
patient
receiv
hlamatch
allogen
hsct
shown
safe
associ
low
incid
signific
acut
gvhd
tocilizumab
avail
clinic
use
may
consid
research
studi
combin
etanercept
corticosteroid
recent
preclin
studi
uncov
possibl
novel
strategi
treat
bo
ibrutinib
food
drug
administrationeapprov
revers
inhibitor
bruton
tyrosin
kinas
induc
cell
kinas
target
cell
b
cell
alloantibodydriven
multiorgansystem
chronic
gvhd
murin
model
induc
bo
ibrutinib
treatment
amelior
pulmonari
fibrosi
curtail
develop
bo
vivo
measur
pulmonari
function
paramet
includ
resist
elast
complianc
anoth
murin
model
bo
promin
manifest
lung
patholog
develop
colonystimul
manner
antiecolonystimul
antibodi
significantli
improv
pulmonari
function
paramet
result
signific
reduct
collagen
deposit
noninvas
posit
pressur
ventil
nippv
increasingli
use
last
decad
support
patient
arf
instanc
help
avoid
endotrach
intub
invas
mechan
ventil
particular
interest
patient
highli
suscept
infect
breach
respiratori
barrier
recent
survey
explor
variat
care
critic
ill
pediatr
hsct
patient
north
america
center
includ
studi
report
use
bontinu
posit
airway
pressur
cpap
bilevel
posit
airway
pressur
bipap
intub
success
rate
defin
absenc
subsequ
endotrach
intub
high
immunecompromis
children
report
cardiovascular
dysfunct
predict
factor
nippv
failur
postallogen
hsct
adult
cohort
earli
initi
noninvas
ventil
associ
better
oxygen
improv
surviv
need
mechan
ventil
benefit
nippv
usual
seen
earli
within
hour
applic
therefor
evolv
pulmonari
dysfunct
patient
risk
figur
prompt
escal
therapi
use
invas
mechan
ventil
nearli
one
half
children
admit
pediatr
icu
transplant
requir
mechan
ventil
common
theme
particularli
true
posttransplant
patient
respiratori
failur
requir
mechan
ventil
clear
earli
derecruit
distal
alveolar
air
space
avail
effect
ga
exchang
pathophysiolog
ip
involv
loss
alveolar
air
space
critic
element
lead
hypoxemia
effort
aim
minim
alveolar
derecruit
includ
judici
use
posit
endexpiratori
pressur
peep
low
tidal
volum
tv
strategi
mlkg
likewis
goal
ventil
may
need
moder
toward
maintain
ph
support
oxygen
satur
landmark
studi
ard
network
evalu
higher
versu
lower
tv
mechan
ventil
demonstr
reduct
mortal
mlkg
ideal
bodi
weight
tv
compar
mlkg
ideal
bodi
weight
tv
achiev
optim
lung
protect
lowest
plateau
pressur
tv
possibl
select
accumul
observ
evid
suggest
tv
limit
mechan
ventil
patientsdeven
ard
peep
set
maxim
alveolar
recruit
avoid
overdistent
judici
use
higher
peep
may
need
clinic
set
dah
engraft
syndrom
highfrequ
oscillatori
ventil
hfov
altern
techniqu
ventil
small
tv
deliv
high
frequenc
hz
oscillatori
pump
thu
highfrequ
oscil
theoret
meet
goal
strategi
lung
protect
ventil
extrem
small
tv
mlkg
constant
lung
recruit
benefit
hfov
treatment
ard
still
controversi
patient
ard
hfov
reduc
hospit
mortal
result
improv
oxygen
measur
partial
arteri
oxygen
saturationinspir
oxygen
fraction
pao
fio
ratio
howev
recent
multicent
random
control
trial
hfov
versu
convent
mechan
ventil
adult
patient
ard
conclud
mortal
actual
higher
patient
receiv
earli
hfov
pediatr
literatur
also
inconclus
mani
center
report
improv
ga
exchang
use
hfov
therefor
use
hfov
may
still
suitabl
rescu
treatment
patient
refractori
hypoxemia
higher
mean
airway
pressur
fio
requir
maintain
oxygen
prone
posit
improv
ventil
perfus
mismatch
help
recruit
depend
lung
region
drain
tracheobronchi
secret
although
earlier
studi
fail
show
surviv
benefit
recent
evid
suggest
interv
prone
posit
patient
sever
ard
reduc
mortal
recent
multicent
random
trial
adult
patient
sever
ard
random
either
standard
supin
interv
prone
posit
protect
mechan
ventil
strategi
implement
group
mortal
significantli
lower
patient
undergo
interv
prone
posit
compar
patient
supin
posit
versu
p
although
prone
posit
may
offer
benefit
treat
children
ard
done
cautious
associ
increas
frequenc
advers
event
airway
obstruct
hypotens
vomit
accident
extub
recent
ard
network
fluid
cathet
treatment
trial
report
conserv
fluid
manag
strategi
compar
liber
fluid
strategi
increas
mean
number
ventilatorfre
day
adult
patient
acut
lung
injuri
versu
day
respect
p
addit
benefici
effect
outcom
studi
found
conserv
fluid
strategi
increas
incid
renal
failur
develop
shock
grow
evid
fluid
overload
critic
ill
children
associ
wors
outcom
larg
seri
critic
ill
children
receiv
continu
renal
replac
therapi
crrt
children
fluid
overload
higher
adjust
mortal
rate
compar
increas
mortal
increas
fluid
overload
crrt
initi
children
transplant
higher
risk
fluid
overload
addit
mani
instanc
manifest
capillari
leak
render
fluid
manag
challeng
retrospect
review
children
transplant
children
acut
renal
failur
fluid
overload
fluid
overload
associ
better
surviv
earli
initi
crrt
treatment
fluid
overload
diuret
therapi
fail
may
help
improv
oxygen
outcom
retrospect
review
institut
includ
posttransplant
pediatr
patient
acut
lung
injuri
underw
crrt
crrt
associ
signific
improv
oxygen
hour
initi
therapi
pao
fio
increas
significantli
median
increas
interv
initi
crrt
compar
interv
crrt
improv
pao
fio
associ
reduct
fluid
balanc
initi
crrt
cohort
pediatr
stem
cell
recipi
autolog
allogen
crrt
survivor
lower
mean
airway
pressur
end
crrt
compar
nonsurvivor
receiv
mechan
ventil
suggest
etiolog
underli
pulmonari
dysfunct
may
influenc
benefici
effect
crrt
benefit
corticosteroid
treat
acut
lung
injuri
controversi
studi
show
clear
benefit
wherea
studi
report
increas
mortal
use
day
onset
ard
metaanalysi
random
trial
use
corticosteroid
ard
show
prolong
corticosteroid
treatment
associ
signific
improv
pao
fio
ratio
well
signific
reduct
durat
mechan
ventil
icu
stay
mortal
adjust
includ
variabl
balanc
control
group
metaanalysi
mortal
diminish
statist
signific
surfact
dysfunct
like
contribut
ip
transtrach
instil
human
surfact
proteina
attenu
manifest
ip
mice
recent
random
doubleblind
control
studi
use
calfact
children
ard
show
improv
oxygen
hospitalfre
day
mortal
rate
post
hoc
analysi
immunecompromis
cohort
children
acut
lung
injuri
suggest
potenti
benefit
calfact
popul
reduc
mortal
improv
oxygen
explor
ongo
multicent
random
trial
investig
use
calfact
children
transplant
extracorpor
membran
oxygen
ecmo
use
children
acut
respiratori
cardiac
failur
convent
method
treatment
fail
risk
mortal
high
report
surviv
rate
children
respiratori
failur
requir
ecmo
howev
children
transplant
undergon
ecmo
significantli
lower
surviv
rate
rang
factor
increas
risk
mortal
includ
longer
durat
intub
initi
ecmo
median
day
higher
peep
hour
initi
ecmo
well
higher
number
organ
dysfunct
ecmo
requir
anticoagul
challeng
transplant
seri
children
transplant
underw
ecmo
bleed
complic
occur
ecmo
consid
earli
cours
sever
respiratori
failur
howev
prognosi
still
poor
mortal
arf
high
rang
tabl
recent
report
largest
singleinstitut
retrospect
review
outcom
pediatr
oncolog
posttransplant
patient
requir
invas
mechan
ventil
document
encourag
steadi
trend
improv
surviv
time
recent
prospect
multicent
studi
report
mortal
rate
sever
impair
oxygen
use
crrt
cytomegaloviru
viremia
independ
predictor
mortal
mortal
patient
arf
transplant
requir
crrt
high
coordin
care
critic
care
transplant
pulmonari
nephrolog
pharmaci
nutrit
servic
imper
improv
outcom
counsel
hsct
patient
famili
perspect
team
member
differ
servic
may
varianc
albeit
complimentari
put
togeth
patient
chronic
lung
diseas
requir
frequent
monitor
symptom
pft
walk
test
clinic
visit
assess
respons
bronchodilatorsteroid
therapi
cardiopulmonari
exercis
test
may
perform
indic
overnight
pulseoximetri
may
consid
assess
need
supplement
oxygen
sleep
hypoxia
may
go
unnot
lead
pulmonari
hypertens
develop
pulmonari
hypertens
associ
bo
lung
transplant
recipi
transthorac
echocardiographi
excel
screen
tool
pulmonari
hypertens
season
influenza
vaccin
protect
pneumococc
titer
may
benefici
respiratori
viral
infect
uncommon
late
allogen
hsct
physic
therapi
build
cardiorespiratori
endur
avoid
activ
passiv
smoke
import
repair
impair
pulmonari
function
recoveri
diffus
capac
carbon
monoxid
observ
year
allogen
hsct
outcom
arf
improv
team
approach
critic
care
transplant
servic
identifi
patient
risk
earli
diagnosi
ip
bal
incorpor
newer
advanc
target
drug
therapi
use
noninvas
posit
pressur
ventil
respiratori
decompens
minim
alveolar
derecruit
mechan
ventil
restrict
fluid
earli
initi
crrt
use
hfov
ecmo
progress
hypoxemia
possibl
cellular
therapi
futur
close
followup
patient
chronic
lung
diseas
financi
disclosur
statement
work
support
nation
cancer
institut
cancer
center
core
support
grant
ca
american
lebanes
syrian
associ
chariti
conflict
interest
statement
conflict
interest
report
authorship
statement
le
contribut
equal
work
consid
cofirst
author
